Abstract Number: 1694 • 2019 ACR/ARP Annual Meeting
Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease
Background/Purpose: This was an exploratory analysis of genetic polymorphisms, plasma biomarkers, and blood leukocytes with clinical response in the phase 3 clinical study CC-10004-BCT-002 (NCT02307513).Methods:…Abstract Number: 1695 • 2019 ACR/ARP Annual Meeting
Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases
Background/Purpose: Oral and/or genital aphthous ulcers are the most common symptoms of Behçet´s disease (BD), and are often refractory to conventional treatment. The inhibitor of…Abstract Number: 1696 • 2019 ACR/ARP Annual Meeting
Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?
Background/Purpose: Tumor necrosis factor (TNF)-α inhibitors are extensively utilized in the treatment of inflammatory rheumatic diseases. These agents increase the risk of tuberculosis (TB), especially…Abstract Number: 1795 • 2018 ACR/ARHP Annual Meeting
New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort
Background/Purpose: Major organ involvement such as vascular or ocular disease, especially in young males, is one of the main causes of mortality and morbidity in…Abstract Number: 1814 • 2018 ACR/ARHP Annual Meeting
Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series
Background/Purpose: Lower extremity deep vein thrombosis (LEDVT) is a disabling complication of Behcet’s syndrome (BS). Relapses are frequent and cause permanent disability due to post-thrombotic…Abstract Number: 1796 • 2018 ACR/ARHP Annual Meeting
Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades
Background/Purpose: There is some evidence that incident Behcet’s syndrome (BS) might be becoming less severe (1, 2). We compared clinical findings at presentation of BS…Abstract Number: 1815 • 2018 ACR/ARHP Annual Meeting
Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center
Background/Purpose: To analyze the clinical features of patients with Behcet’s disease(BD) complicated with aneurysmal lesions. Methods: We retrospectively reviewed the clinical data of patients with…Abstract Number: 1797 • 2018 ACR/ARHP Annual Meeting
An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome
Background/Purpose: Pulmonary artery involvement (PAI) is the most common form of arterial involvement in Behçet’s syndrome (BS). A previous survey (1) by our group had…Abstract Number: 1975 • 2018 ACR/ARHP Annual Meeting
Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations
Background/Purpose: Behçet’s disease is a multisystem disease affecting young adults with variable vessel vasculitis as its underlying pathology. Previous studies in Behçet’s disease linked it…Abstract Number: 1798 • 2018 ACR/ARHP Annual Meeting
Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients
Background/Purpose: Formal experience with leg ulcers in Behcet’s syndrome (BS) is limited. It is a relatively rare complication that can be seen during the course…Abstract Number: 2166 • 2018 ACR/ARHP Annual Meeting
Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review
Background/Purpose: Venous thrombosis (VT) is a serious and potentially life-threatening manifestation of Behçet disease (BD). However, there is little evidence of the management of the…Abstract Number: 1799 • 2018 ACR/ARHP Annual Meeting
Increased Vein Wall Thickness in Behçet’s Syndrome
Background/Purpose: Lower extremity vein thrombosis (LEVT) is the key feature of vascular involvement in Behçet’s syndrome (BS).Vein wall thickness (VWT) is proposed to be a…Abstract Number: 2269 • 2018 ACR/ARHP Annual Meeting
Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients
Background/Purpose: Retinal vasculitis is a serious complication of uveitis due to Behçet’s disease (BD). The treatment is based on corticosteroids, conventional immunosuppressants (IS) and anti-TNF-α…Abstract Number: 1801 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis
Background/Purpose: Uveitis in Behçet’s syndrome (BS) follows a recurrent disease course with inflammatory exacerbations causing damage in the uvea, retina and optic nerve even with…Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study
Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »